H6PD (O95479) variants and mutations
H6PD (also known as O95479) is a human protein-coding gene encoding a GDH/6PGL endoplasmic bifunctional protein. It generates NADPH within the endoplasmic-reticulum lumen, supporting local redox reactions including prereceptor glucocorticoid metabolism. Biallelic loss-of-function variants can cause cortisone reductase deficiency with compensatory androgen excess and features such as premature pseudopuberty or polycystic-ovary-like symptoms. This analysis covers 1,425 H6PD variants and mutations. Of these, 96% have computational variant effect predictions. Disease context includes Hyperandrogenism due to cortisone reductase deficiency, Abnormality of the skeletal system, and obesity disorder. Example H6PD variants include W2*, W2R, and W2G.
Variant analysis overview
- Gene: H6PD
- Protein: O95479
- UniProt accession: O95479
- Organism: Homo sapiens
- Variants analyzed: 1425
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 1,159 unspecified-consequence records; 25 frameshift variants; 106 synonymous variants; 127 missense variants; 5 stop-gained variants; 2 in-frame deletions; 1 splice-region variants
- Prediction scores: 1,364 variants have prediction scores (96% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Hyperandrogenism due to cortisone reductase deficiency, Abnormality of the skeletal system, obesity disorder, neurodegenerative disease, stroke disorder, alcohol drinking, placental retention, autoimmune disorder of central nervous system, hereditary disease, venous thromboembolism, ventral hernia, Inguinal hernia.
Protein structure and variant hotspots
- Protein features: 11 binding sites; 5 post-translational modification sites.
- PTM context: 9 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable H6PD variants
Examples include W2*, W2R, W2G, W2C, N3S, N3T, N3H, N3D. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- W2* (p.Trp2Ter), gnomAD rs1307163367, CADD 40.00
- W2R (p.Trp2Arg), gnomAD rs1424973963, REVEL 0.52, MetaLR 0.85
- W2G (p.Trp2Gly), rs1213763285, gnomAD 1-9240017-T-G, CADD 17.10, SIFT 0.05
- W2C (p.Trp2Cys), gnomAD 1-9244940-G-C, REVEL 0.45, MetaLR 0.88
- N3S (p.Asn3Ser), gnomAD rs1641114677, REVEL 0.26, MetaLR 0.75
- N3T (p.Asn3Thr), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10107, REVEL 0.27, MetaLR 0.75, Variant assessed as somatic; moderate impact.
- N3H (p.Asn3His), gnomAD 1-9240014-A-C, CADD 9.63, SIFT 0.07
- N3D (p.Asn3Asp), gnomAD 1-9240014-A-G, CADD 3.09, SIFT 0.35
- N3K (p.Asn3Lys), gnomAD 1-9240016-C-A, CADD 3.69, SIFT 1.00
- M4T (p.Met4Thr), gnomAD 1-9244945-T-C, REVEL 0.58, MetaLR 0.88
- L5* (p.Leu5Ter), gnomAD 1-9239998-GT-G, CADD 21.60
- L5L (p.Leu5Leu), gnomAD 1-9239999-T-C, CADD 5.82
- L5V (p.Leu5Val), gnomAD 1-9244947-C-G, REVEL 0.49, MetaLR 0.88
- I6R (p.Ile6Arg), ESP rs75652807, ExAC rs75652807, TOPMed rs75652807, gnomAD rs75652807
- I6T (p.Ile6Thr), ESP rs75652807, ExAC rs75652807, TOPMed rs75652807, gnomAD rs75652807, REVEL 0.17, MetaLR 0.61
- I6V (p.Ile6Val), cosmic curated COSV10611, MetaLR 0.67, MetaSVM -0.02
- V7A (p.Val7Ala), Ensembl rs1641115004, REVEL 0.25, MetaLR 0.73
- V7M (p.Val7Met), TOPMed rs1641114916, REVEL 0.23, MetaLR 0.84
- V7L (p.Val7Leu), gnomAD 1-9244953-G-C, REVEL 0.22, MetaLR 0.83
- A8V (p.Ala8Val), cosmic curated COSV66232, ExAC rs762627876, TOPMed rs762627876, gnomAD rs762627876, REVEL 0.31, MetaLR 0.87
- A8T (p.Ala8Thr), gnomAD 1-9240002-G-A, CADD 20.90, SIFT 0.02
- A8S (p.Ala8Ser), gnomAD 1-9240002-G-T, CADD 18.70, SIFT 0.13
- A8E (p.Ala8Glu), gnomAD 1-9240003-C-A, CADD 20.20, SIFT 0.01
- A8A (p.Ala8Ala), gnomAD 1-9240004-A-G, CADD 8.04
- M9I (p.Met9Ile), Ensembl rs1641115467
- M9T (p.Met9Thr), ExAC rs763666648, TOPMed rs763666648, gnomAD rs763666648, REVEL 0.34, MetaLR 0.84
- M9V (p.Met9Val), Ensembl rs1641115284, MetaLR 0.67, MetaSVM -0.02
- C10Y (p.Cys10Tyr), TOPMed rs966406932, REVEL 0.39, MetaLR 0.86
- C10S (p.Cys10Ser), rs760670274, gnomAD 1-9244962-TG-T, CADD 22.60
- L11V (p.Leu11Val), rs138547645, ClinGen CA574869, ClinVar RCV002964017, ESP rs138547645, REVEL 0.18, MetaLR 0.67, Likely benign, Inborn genetic diseases
- A12D (p.Ala12Asp), ExAC rs766927941, TOPMed rs766927941, gnomAD rs766927941, REVEL 0.65, MetaLR 0.87
- A12T (p.Ala12Thr), ExAC rs761439328, gnomAD rs761439328, REVEL 0.31, MetaLR 0.86
- A12V (p.Ala12Val), ExAC rs766927941, TOPMed rs766927941, gnomAD rs766927941, REVEL 0.34, MetaLR 0.87
- A12A (p.Ala12Ala), rs1641116199, gnomAD 1-9244970-C-T, CADD 8.92
- L13F (p.Leu13Phe), Ensembl rs2100326565
- L13P (p.Leu13Pro), gnomAD rs1274194727, REVEL 0.72, MetaLR 0.90
- L13R (p.Leu13Arg), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10107, MetaLR 0.87, MetaSVM 0.55, Variant assessed as somatic; moderate impact.
- L14P (p.Leu14Pro), gnomAD rs1482255069, REVEL 0.62, MetaLR 0.86
- L14Q (p.Leu14Gln), gnomAD rs1482255069, MetaLR 0.87, MetaSVM 0.57
- L14V (p.Leu14Val), gnomAD 1-9244974-C-G, REVEL 0.35, MetaLR 0.89
- G15C (p.Gly15Cys), TOPMed rs1179343463, gnomAD rs1179343463, REVEL 0.59, MetaLR 0.87
- G15D (p.Gly15Asp), NCI-TCGA Cosmic COSV6623, cosmic curated COSV66231, MetaLR 0.82, MetaSVM 0.75, Variant assessed as somatic; moderate impact.
- C16C (p.Cys16Cys), rs1570087797, gnomAD 1-9244982-C-T, CADD 10.30
- C16W (p.Cys16Trp), gnomAD 1-9244982-C-G, REVEL 0.16, MetaLR 0.15
- L17L (p.Leu17Leu), gnomAD 1-9244983-C-T, CADD 9.14
- Q18K (p.Gln18Lys), gnomAD 1-9244986-C-A, REVEL 0.06, MetaLR 0.15
- Q18P (p.Gln18Pro), gnomAD 1-9244987-A-C, REVEL 0.11, MetaLR 0.14
- Q18R (p.Gln18Arg), gnomAD 1-9244987-A-G, REVEL 0.07, MetaLR 0.13
- Q18Q (p.Gln18Gln), rs1570087838, gnomAD 1-9244988-A-G, CADD 7.07
- A19G (p.Ala19Gly), ExAC rs778041712, TOPMed rs778041712, gnomAD rs778041712, REVEL 0.07, MetaLR 0.21
- A19T (p.Ala19Thr), cosmic curated COSV10532, MetaLR 0.24, MetaSVM -0.64
- A19V (p.Ala19Val), ExAC rs778041712, TOPMed rs778041712, gnomAD rs778041712, REVEL 0.12, MetaLR 0.25
- Q20P (p.Gln20Pro), TOPMed rs1423782229, gnomAD rs1423782229, REVEL 0.14, MetaLR 0.15
- Q20R (p.Gln20Arg), TOPMed rs1423782229, gnomAD rs1423782229, REVEL 0.06, MetaLR 0.18
- Q20L (p.Gln20Leu), gnomAD 1-9244993-A-T, REVEL 0.10, MetaLR 0.14
- E21K (p.Glu21Lys), NCI-TCGA Cosmic COSV6623, cosmic curated COSV66230, MetaLR 0.15, MetaSVM -0.81, Variant assessed as somatic; moderate impact.
- E21D (p.Glu21Asp), gnomAD 1-9240007-G-T, CADD 14.90, SIFT 0.04
- E21E (p.Glu21Glu), rs1570087898, gnomAD 1-9244997-G-A, CADD 2.80
- L22F (p.Leu22Phe), Ensembl rs866086771, MetaLR 0.12, MetaSVM -1.00
- L22L (p.Leu22Leu), gnomAD 1-9245000-C-G, CADD 5.73
- Q23K (p.Gln23Lys), Ensembl rs1570087918
- Q23R (p.Gln23Arg), TOPMed rs1254407285, MetaLR 0.09, MetaSVM -1.02
- Q23L (p.Gln23Leu), gnomAD 1-9245002-A-T, REVEL 0.07, MetaLR 0.11
- Q23Q (p.Gln23Gln), rs780015179, gnomAD 1-9245003-G-A, CADD 5.59
- G24E (p.Gly24Glu), TOPMed rs1641117965, REVEL 0.32, MetaLR 0.20
- H25R (p.His25Arg), Ensembl rs1641118132, REVEL 0.24, MetaLR 0.16
- H25P (p.His25Pro), gnomAD 1-9244926-CA-C, CADD 15.60
- H25Q (p.His25Gln), rs770903607, gnomAD 1-9244928-C-G, CADD 20.50, SIFT 0.02
- H25Y (p.His25Tyr), gnomAD 1-9245007-C-T, REVEL 0.20, MetaLR 0.23
- H25H (p.His25His), gnomAD 1-9245009-T-C, CADD 1.32
- V26G (p.Val26Gly), gnomAD rs1369751665, REVEL 0.51, MetaLR 0.32
- V26A (p.Val26Ala), gnomAD 1-9245011-T-C, REVEL 0.24, MetaLR 0.18
- S27F (p.Ser27Phe), rs1444732814, ClinGen CA338187088, ClinVar RCV002735411, TOPMed rs1444732814, REVEL 0.48, MetaLR 0.49, Uncertain significance, not provided
- S27H (p.Ser27His), gnomAD 1-9245010-GTC-G, CADD 27.30
- S27P (p.Ser27Pro), gnomAD 1-9245013-T-C, REVEL 0.44, MetaLR 0.42
- S27C (p.Ser27Cys), gnomAD 1-9245014-C-G, REVEL 0.37, MetaLR 0.41
- S27S (p.Ser27Ser), rs1167500801, gnomAD 1-9245015-C-T, CADD 8.69
- I28V (p.Ile28Val), gnomAD 1-9245016-A-G, REVEL 0.14, MetaLR 0.15
- I28M (p.Ile28Met), gnomAD 1-9245018-A-G, REVEL 0.32, MetaLR 0.22
- I29V (p.Ile29Val), gnomAD 1-9245019-A-G, REVEL 0.05, MetaLR 0.05
- I29T (p.Ile29Thr), gnomAD 1-9245020-T-C, REVEL 0.29, MetaLR 0.22
- L30L (p.Leu30Leu), rs911676820, gnomAD 1-9245024-G-A, CADD 6.96
- L31M (p.Leu31Met), TOPMed rs944435283, gnomAD rs944435283, REVEL 0.34, MetaLR 0.40
- L31P (p.Leu31Pro), TOPMed rs986457260, gnomAD rs986457260, REVEL 0.72, MetaLR 0.52
- L31L (p.Leu31Leu), rs944435283, gnomAD 1-9245025-C-T, CADD 9.06
- G32E (p.Gly32Glu), gnomAD 1-9245029-G-A, REVEL 0.95, MetaLR 0.89
- G32G (p.Gly32Gly), rs758708481, gnomAD 1-9245030-A-C, CADD 10.70
- A33E (p.Ala33Glu), ExAC rs778117935, gnomAD rs778117935, REVEL 0.75, MetaLR 0.67
- A33V (p.Ala33Val), gnomAD 1-9245032-C-T, REVEL 0.66, MetaLR 0.58
- T34A (p.Thr34Ala), cosmic curated COSV66231, TOPMed rs1415976499, MetaLR 0.47, MetaSVM 0.08
- G35G (p.Gly35Gly), rs1384996921, gnomAD 1-9245039-G-A, CADD 7.57
- D36N (p.Asp36Asn), Ensembl rs2100327025, MetaLR 0.59, MetaSVM 0.24
- D36H (p.Asp36His), gnomAD 1-9245040-G-C, REVEL 0.91, MetaLR 0.76
- L37V (p.Leu37Val), TOPMed rs1041255281, MetaLR 0.99, MetaSVM 1.04
- L37L (p.Leu37Leu), rs1041255281, gnomAD 1-9245043-C-T, CADD 9.46
- A38V (p.Ala38Val), gnomAD 1-9245047-C-T, REVEL 0.77, MetaLR 0.62
- K40K (p.Lys40Lys), rs747192090, gnomAD 1-9245054-G-A, CADD 8.34
- Y41* (p.Tyr41Ter), gnomAD rs1641119972, CADD 37.00
- Y41D (p.Tyr41Asp), Ensembl rs1641119871, REVEL 0.89, MetaLR 0.95
- L42S (p.Leu42Ser), gnomAD rs1340364931, REVEL 0.95, MetaLR 0.98
- L42V (p.Leu42Val), gnomAD 1-9245058-T-G, REVEL 0.71, MetaLR 0.96
- L42L (p.Leu42Leu), rs1570088162, gnomAD 1-9245058-T-C, CADD 9.34
- W43* (p.Trp43Ter), gnomAD rs1252321067, CADD 39.00
- W43G (p.Trp43Gly), ExAC rs771086344, TOPMed rs771086344, gnomAD rs771086344, REVEL 0.93, MetaLR 0.95, Uncertain significance
- W43R (p.Trp43Arg), rs771086344, ClinGen CA574879, ClinVar RCV003260329, ClinVar RCV006474146, REVEL 0.94, MetaLR 0.95, Uncertain significance, not provided; Inborn genetic diseases
- Q44* (p.Gln44Ter), ExAC rs746398496, TOPMed rs746398496, gnomAD rs746398496, CADD 37.00
- Q44K (p.Gln44Lys), ExAC rs746398496, TOPMed rs746398496, gnomAD rs746398496, REVEL 0.33, MetaLR 0.34
- Q44P (p.Gln44Pro), ExAC rs778375210, TOPMed rs778375210, gnomAD rs778375210, REVEL 0.32, MetaLR 0.06
- Q44R (p.Gln44Arg), ExAC rs778375210, TOPMed rs778375210, gnomAD rs778375210, REVEL 0.45, MetaLR 0.33
- G45E (p.Gly45Glu), TOPMed rs1245519061, gnomAD rs1245519061, REVEL 0.96, MetaLR 0.97
- G45R (p.Gly45Arg), ExAC rs199815320, TOPMed rs199815320, gnomAD rs199815320, REVEL 0.96, MetaLR 0.97
- G45V (p.Gly45Val), TOPMed rs1245519061, gnomAD rs1245519061, MetaLR 0.96, MetaSVM 1.10
- G45G (p.Gly45Gly), rs763242960, gnomAD 1-9245069-A-G, CADD 1.32
- L46R (p.Leu46Arg), gnomAD rs1387917209
- L46V (p.Leu46Val), gnomAD rs1187418376, MetaLR 0.57, MetaSVM 0.41
- L46L (p.Leu46Leu), rs1641123215, gnomAD 1-9245072-G-C, CADD 2.58
- F47L (p.Phe47Leu), gnomAD 1-9240009-CT-C, CADD 14.30
- F47F (p.Phe47Phe), rs1640951599, gnomAD 1-9240013-T-C, CADD 7.99
- Q48S (p.Gln48Ser), gnomAD 1-9245074-TC-T, CADD 24.90
- Q48* (p.Gln48Ter), gnomAD 1-9245076-C-T, CADD 37.00
- L49M (p.Leu49Met), cosmic curated COSV66231, gnomAD rs1429972842, MetaLR 0.98, MetaSVM 1.07
- L49L (p.Leu49Leu), rs1357825813, gnomAD 1-9245081-G-A, CADD 5.87
- Y50Y (p.Tyr50Tyr), gnomAD 1-9245084-C-T, CADD 7.75
- L51V (p.Leu51Val), gnomAD 1-9245085-C-G, REVEL 0.27, MetaLR 0.84
- D52E (p.Asp52Glu), gnomAD 1-9245090-T-G, REVEL 0.31, MetaLR 0.74
- A54V (p.Ala54Val), rs140077792, cosmic curated COSV10611, 1000Genomes rs140077792, ESP rs140077792, REVEL 0.04, MetaLR 0.08, Uncertain significance, not provided
- A54T (p.Ala54Thr), gnomAD 1-9245094-G-A, REVEL 0.11, MetaLR 0.19
- A54A (p.Ala54Ala), rs200780666, gnomAD 1-9245096-G-A, CADD 0.16
- G55G (p.Gly55Gly), gnomAD 1-9245099-G-A, CADD 2.73
- R56K (p.Arg56Lys), Ensembl rs1570088377
- G57A (p.Gly57Ala), TOPMed rs1641124418, REVEL 0.17, MetaLR 0.22
- G57S (p.Gly57Ser), TOPMed rs749808170, gnomAD rs749808170, REVEL 0.18, MetaLR 0.19, Uncertain significance, Inborn genetic diseases
- G57V (p.Gly57Val), gnomAD 1-9245104-G-T, REVEL 0.30, MetaLR 0.39
- G57D (p.Gly57Asp), gnomAD 1-9245104-G-A, REVEL 0.13, MetaLR 0.16
- G57G (p.Gly57Gly), rs761339618, gnomAD 1-9245105-T-C, CADD 9.33
- H58Y (p.His58Tyr), ESP rs375333419, ExAC rs375333419, gnomAD rs375333419, REVEL 0.06, MetaLR 0.18
- H58S (p.His58Ser), rs766269667, gnomAD 1-9245100-A-AG, CADD 23.50
- S59G (p.Ser59Gly), ExAC rs749851354, TOPMed rs749851354, gnomAD rs749851354, REVEL 0.42, MetaLR 0.88, Uncertain significance, Inborn genetic diseases
- S59T (p.Ser59Thr), gnomAD 1-9245110-G-C, REVEL 0.28, MetaLR 0.71
- F60C (p.Phe60Cys), TOPMed rs975750869, gnomAD rs975750869, REVEL 0.91, MetaLR 0.96
- F60Y (p.Phe60Tyr), TOPMed rs975750869, gnomAD rs975750869, REVEL 0.75, MetaLR 0.96
- F60L (p.Phe60Leu), rs753622383, gnomAD 1-9245110-GT-G, CADD 22.60
- F60V (p.Phe60Val), gnomAD 1-9245112-T-G, REVEL 0.81, MetaLR 0.94
- S61S (p.Ser61Ser), rs1262371619, gnomAD 1-9245117-C-T, CADD 10.30
- F62F (p.Phe62Phe), rs116196265, gnomAD 1-9245120-C-T, CADD 8.38
- H63R (p.His63Arg), ExAC rs766362601, TOPMed rs766362601, gnomAD rs766362601, REVEL 0.69, MetaLR 0.89
- H63Y (p.His63Tyr), Ensembl rs2100327763, MetaLR 0.70, MetaSVM 0.04
- H63H (p.His63His), rs753816269, gnomAD 1-9245123-T-C, CADD 0.67
- G64* (p.Gly64Ter), NCI-TCGA Cosmic COSV6623, cosmic curated COSV66232, Variant assessed as somatic; high impact.
- A65T (p.Ala65Thr), gnomAD 1-9245127-G-A, REVEL 0.31, MetaLR 0.77
- A65P (p.Ala65Pro), gnomAD 1-9245127-G-C, REVEL 0.71, MetaLR 0.94
- A65A (p.Ala65Ala), rs545499440, gnomAD 1-9245129-T-G, CADD 9.21
- A66S (p.Ala66Ser), gnomAD rs1231573519, REVEL 0.79, MetaLR 0.96
- A66V (p.Ala66Val), TOPMed rs1265494836, gnomAD rs1265494836, REVEL 0.88, MetaLR 0.98
- T68A (p.Thr68Ala), NCI-TCGA TCGA novel, REVEL 0.09, MetaLR 0.20, Variant assessed as somatic; moderate impact.
- T68R (p.Thr68Arg), gnomAD 1-9245137-C-G, REVEL 0.13, MetaLR 0.17
- T68T (p.Thr68Thr), rs1037438406, gnomAD 1-9245138-A-C, CADD 5.50
- A69T (p.Ala69Thr), gnomAD rs1462197453, REVEL 0.03, MetaLR 0.09
- A69A (p.Ala69Ala), gnomAD 1-9245141-C-A, CADD 7.96
- P70L (p.Pro70Leu), rs1165969718, ClinGen CA338187385, ClinVar RCV004396856, TOPMed rs1165969718, REVEL 0.39, MetaLR 0.65, Uncertain significance, Inborn genetic diseases
- P70S (p.Pro70Ser), cosmic curated COSV66231, MetaLR 0.77, MetaSVM 0.37
- P70P (p.Pro70Pro), gnomAD 1-9245144-C-T, CADD 7.00
- K71Q (p.Lys71Gln), Ensembl rs1570088601, MetaLR 0.09, MetaSVM -1.04
- K71R (p.Lys71Arg), rs201786227, TOPMed rs201786227, gnomAD rs201786227, REVEL 0.06, MetaLR 0.14, Variant assessed as somatic; moderate impact.
- Q72R (p.Gln72Arg), Ensembl rs1641127154, REVEL 0.09, MetaLR 0.15
- G73R (p.Gly73Arg), rs906651065, ClinGen CA338187412, ClinVar RCV002857085, AlphaMissense 0.15, MetaLR 0.94, Uncertain significance, not provided
- G73S (p.Gly73Ser), TOPMed rs906651065, gnomAD rs906651065, REVEL 0.69, AlphaMissense 0.15
- G73D (p.Gly73Asp), gnomAD 1-9245152-G-A, REVEL 0.63, MetaLR 0.91
- G73A (p.Gly73Ala), gnomAD 1-9245152-G-C, REVEL 0.63, MetaLR 0.91
- Q74* (p.Gln74Ter), TOPMed rs1451746210, gnomAD rs1451746210, CADD 37.00
- Q74Q (p.Gln74Gln), rs778542653, gnomAD 1-9245156-A-G, CADD 6.73
- E75K (p.Glu75Lys), Ensembl rs1570088676, MetaLR 0.81, MetaSVM 0.09
- E75Q (p.Glu75Gln), gnomAD 1-9245157-G-C, REVEL 0.21, MetaLR 0.84
- E75E (p.Glu75Glu), rs909378546, gnomAD 1-9245159-G-A, CADD 8.93
- L76H (p.Leu76His), TOPMed rs1386319292, gnomAD rs1386319292, REVEL 0.46, MetaLR 0.94
- L76V (p.Leu76Val), ExAC rs751860747, gnomAD rs751860747, REVEL 0.16, MetaLR 0.81, Uncertain significance, Inborn genetic diseases
- M77I (p.Met77Ile), ExAC rs757374323, TOPMed rs757374323, gnomAD rs757374323, REVEL 0.32, MetaLR 0.72
- M77T (p.Met77Thr), TOPMed rs1641128093, REVEL 0.46, MetaLR 0.86
- M77L (p.Met77Leu), gnomAD 1-9245163-A-C, REVEL 0.34, MetaLR 0.68
- M77R (p.Met77Arg), gnomAD 1-9245164-T-G, REVEL 0.53, MetaLR 0.80
Public H6PD analysis runs
- H6PD analysis run — H6PD (1,425 variants) — completed 2026-08-19